Abstract: In one embodiment, the present disclosure provides pharmaceutical compositions for suppressing the progression of fibrosis in systemic sclerosis, which contain an antibody against IL-31 receptor A as an active ingredient. In another embodiment, the present disclosure provides pharmaceutical compositions for suppressing Th2 polarization to suppress the progression of fibrosis in systemic sclerosis, which comprise an antibody against IL-31 receptor A as an active ingredient. In a certain embodiment, the above-mentioned antibody is an antibody having a neutralizing activity against IL-31 receptor A.

Abstract: The present invention relates to a nasal polyps reducing agent containing a polysaccharide selected from a polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate (PPS), chondroitin, glucomannan, inulin and xylo-oligosaccharide, or a salt thereof as an active ingredient, a pharmaceutical composition, a method for reducing nasal polyps or a method for preventing/treating nasal polyps. According to the present invention, it is possible to provide an effective and safe nasal polyps reducing agent.

Abstract: An object of the present invention is mainly to provide a medical skin external preparation that is suitable for treating superficial skin infections, in particular, superficial skin infections accompanied by blister or erosion, etc. For example, the present invention can provide a medical skin external preparation containing 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid and/or a pharmaceutically acceptable salt thereof as an active ingredient, and an alcohol and/or a fatty acid having 12 or more carbon atoms.

Abstract: The present invention is intended mainly to provide an external preparation that exerts a therapeutic and/or preventive effect against dermatological infections such as acne involving suppurative inflammation, and superficial infections of the skin upon being administered to a human patient once daily. For example, the present invention is an external preparation that comprises 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid and/or a pharmaceutically acceptable salt thereof as an active ingredient, and that exerts a therapeutic and/or preventive effect against a dermatological infection upon being administered to a human patient once daily.

Abstract: The present invention aims to provide a cyclosporine external preparation showing improved transdermal absorbability of cyclosporine. The present invention provides an external preparation containing cyclosporine and a ketone.

Abstract: A deformed nail corrector 1A for correcting a deformed nail includes a first hook 2, a second hook 3, a tube-like flexible member 4 joined at one end to the first hook 2 and at the other end to the second hook 3, and a superelastic wire member 5 inserted in the flexible member 4, and the flexible member 4 is stretchable so as to allow the distance between the first hook 2 and second hook 3 to be changed.

Abstract: The present invention is intended to provide a cyclosporine external preparation that improves transdermal absorption of cyclosporine. The present invention provides an external preparation containing cyclosporine, ethanol, and a fatty acid monoester.

Abstract: The present invention is intended mainly to provide an external preparation that exerts a therapeutic and/or preventive effect against dermatological infections such as acne involving suppurative inflammation, and superficial infections of the skin upon being administered to a human patient once daily. For example, the present invention is an external preparation that comprises 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid and/or a pharmaceutically acceptable salt thereof as an active ingredient, and that exerts a therapeutic and/or preventive effect against a dermatological infection upon being administered to a human patient once daily.

Abstract: Provided is an ointment which has excellent drug stability and excellent drug uniformity. The ointment, which comprises 1 to 5% by weight of 1-[2-[(4S)-4-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(hydroxymethyl)-6,7-dimethoxynaphthalene·3/2 hydrate, 3 to 7% by weight of a separation inhibitor, 15 to 50% by weight of a hydrocarbon gel, a pH controller and 0.05 to 0.4% by weight of an antioxidant, has excellent drug stability and excellent drug dispersibility. In the present ointment, polyoxyethylene (196) polyoxypropylene (67) glycol is preferred as the separation inhibitor, diisopropanolamine is preferred as the pH controller, and dibutylhydroxytoluene is preferred as the antioxidant.

Abstract: The present invention aims to provide a cyclosporine external preparation showing improved transdermal absorbability of cyclosporine. The present invention provides an external preparation containing cyclosporine and a ketone.

Abstract: A deformed nail corrector for correcting a deformed nail is provided that includes: a first elastic wire which has one end portion thereof fixed to one edge of the deformed nail in a width direction; a second elastic wire which has one end portion thereof fixed to the other edge of the deformed nail in the width direction; and a binding means which binds the first and second elastic wires to each other and is slidable along the first and second elastic wires in a bound state. The first and second elastic wires are brought into a state where the first and second wires are deformed along the deformed nail with the first and second, elastic wires being in a corrector mounting state where the first and second elastic wires are bound to each other by the binding means.

Abstract: A deformed nail corrector for correcting a deformed nail is provided that includes: a first elastic wire which has one end portion thereof fixed to one edge of the deformed nail in a width direction; a second elastic wire which has one end portion thereof fixed to the other edge of the deformed nail in the width direction; and a binding means which binds the first and second elastic wires to each other and is slidable along the first and second elastic wires in a bound state. The first and second elastic wires are brought into a state where the first and second wires are deformed along the deformed nail with the first and second, elastic wires being in a corrector mounting state where the first and second elastic wires are bound to each other by the binding means.

Abstract: It is intended to provide a lotion preparation which exerts an excellent antibacterial effect, is excellent in the stability of active ingredient and does not contain an additive having a safety problem. The lotion preparation contains (a) 1-cyclo-propyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid and/or a pharmaceutically acceptable salt thereof, (b) a lower alcohol, (c) a water-soluble polymer and (d) a polyhydric alcohol and the pH of the preparation is in the range of 9 to 12.

Abstract: Provided is a novel pharmaceutical composition (antipruritic agent) that is useful for prophylaxis or treatment of itch in conditions such as dermal pruritus. More specifically, provided is a pharmaceutical composition (antipruritic agent) for treatment of itch comprising as an active ingredient a naphthalene compound of the following formula (I): wherein the ring A is a heterocyclic group of the following formula: a hydrate thereof or a pharmaceutically acceptable salt thereof.

Abstract: Provided is a lotion that exhibits high percutaneous absorption inherent in maxacalcitol, allows the maxacalcitol to be stable, and exhibits less dripping when it is applied to heads. A basic oil-in-water emulsion lotion containing 22-oxa-1?, 25-dihydroxyvitamin D3, medium-chain triglyceride, a nonionic surfactant, and a water-soluble thickener and a method of treatment of skin disorders using the same.

Abstract: The present invention provides a dermal composition comprising a polymeric reversed micelle that allows a water-soluble drug to be efficiently encapsulated and that is superior in percutaneous absorptiveness and very safe, and provides a method that can produce the composition in simple steps. The dermal composition comprises a polymeric reversed micelle composed of an amphipathic polymer having a hydrophilic segment and a hydrophobic segment, wherein the polymeric reversed micelle has a configuration in which the hydrophilic segment is the core and the hydrophobic segment is the shell, and a water-soluble drug is encapsulated therein. The composition can be produced by blending an oil phase comprising the amphipathic polymer in an oily base agent with an aqueous phase comprising the water-soluble drug in an aqueous solvent, or by blending an oily base agent with an aqueous phase comprising the amphipathic polymer and the water-soluble drug in an aqueous solvent.

Abstract: The purpose is to provide a tacrolimus-containing pharmaceutical composition which is a creamy preparation for external application having good feeling upon use and has high stability of a main ingredient contained therein (high main ingredient residual ratio), and allows easy control of skin concentration of the main ingredient. The present invention relates to an oil-in-water type creamy composition comprising (A) tacrolimus, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, (B) an oil prepared by mixing (a) a medium-chain fatty acid triglyceride with (b) ethylene glycol salicylate and/or diisopropyl sebacate, (C) an emulsifying agent having a HLB value of 12 or more, and (D) a hydrophilic polymer, and having a pH value of 4 to 7.

Abstract: The ? antigen-encoding gene and the ? antigen protein suppress the production of interleukin-4 etc., improve the Th2 type cytokine-dominant state, and furthermore inhibit various conditions of allergic diseases such as IgE production, histamine release and eosinophil infiltration, and therefore they are very effective for the prevention or treatment of atopic diseases such as atopic dermatitis, asthma, allergic rhinitis, and allergic conjunctivitis, and more broadly allergic diseases.

Abstract: The ? antigen-encoding gene and the ? antigen protein suppress the production of interleukin-4 etc., improve the Th2 type cytokine-dominant state, and furthermore inhibit various conditions of allergic diseases such as IgE production, histamine release and eosinophil infiltration, and therefore they are very effective for the prevention or treatment of atopic diseases such as atopic dermatitis, asthma, allergic rhinitis, and allergic conjunctivitis, and more broadly allergic diseases.

Abstract: Provided is a lotion that exhibits high percutaneous absorption inherent in maxacalcitol, allows the maxacalcitol to be stable, and exhibits less dripping when it is applied to heads. A basic oil-in-water emulsion lotion containing 22-oxa-1?,25-dihydroxyvitamin D3, medium-chain triglyceride, a nonionic surfactant, and a water-soluble thickener and a method of treatment of skin disorders using the same.